Inmeth Suppositories contain Indomethacin 50mg, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe pain, inflammation, and fever. Indomethacin exerts its therapeutic effects by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins, which are mediators of inflammation and pain. This formulation is particularly useful in patients who are unable to take oral medications due to gastrointestinal disturbances or postoperative conditions. Inmeth Suppositories are commonly prescribed for conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gouty arthritis, and acute musculoskeletal injuries. The rectal route allows for rapid absorption and bypasses first-pass metabolism, potentially enhancing bioavailability and reducing gastrointestinal side effects. Dosage should be individualized based on the severity of symptoms and patient response, with careful consideration of contraindications including hypersensitivity to indomethacin, active gastrointestinal bleeding, and severe renal or hepatic impairment. Caution is advised in patients with cardiovascular risk factors. Common adverse effects may include rectal irritation, nausea, dizziness, and headache. Use during pregnancy and lactation should be avoided unless clearly necessary. Patients should be monitored regularly for therapeutic efficacy and potential adverse reactions during treatment with Inmeth Suppositories.